Advanced Accelerator (NASDAQ:AAAP) Given Buy Rating At Canaccord Genuity, Is a Move on The Horizon?

Share

How Canaccord Genuity Currently Rates Advanced Accelerator (NASDAQ:AAAP)

New York: Advanced Accelerator (NASDAQ:AAAP) coverage was initiated with a Buy rating by investment advisers at Canaccord Genuity. This was revealed to clients in a note on Monday morning.

The stock closed the day at $26.5 during the previous session. It is down 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.

Advanced Accelerator (NASDAQ:AAAP) Given Buy Rating At Canaccord Genuity, Is a Move on The Horizon?

Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.02 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.” Get a free copy of the Zacks research report on Advanced Accelerator Application SA(ADR) (AAAP).

COMMENTS: